Establishment Labs to Celebrate 10 Years of Motiva Safety Data at Plastic Surgeon Virtual Symposium

Event to Feature Members of Company’s Medical and Scientific Advisory Boards and U.S. IDE Medical Director

SANTA BARBARA, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it will host a virtual symposium on October 21, 2020 to present ten years of world-wide clinical and real world data for its Motiva® silicone breast implants.

The event, “Motiva: A Decade of Contributions to Women’s Health,” will feature presentations by members of the Company’s Medical Advisory Board, Scientific Advisory Board and independent plastic surgeons who will speak about their clinical data and long-term experiences using the Company’s innovative products.

Panel members scheduled to participate include Brian Kinney, MD, FACS; Prof. Marcos Sforza, MD; Dennis Hammond, MD, FACS; Charles Randquist, MD; Giovanni Botti, MD; and Manuel Chacón, MD.  The symposium will also include remarks by Caroline Glicksman, MD, FACS, Medical Director for the Motiva Implants® U.S. clinical trial, which is studying the safety and effectiveness of the Motiva Implants® SmoothSilk® Round and Ergonomix® silicone gel-filled breast implants in augmentation, reconstruction and revision surgery.

Event Details

Date: Wednesday, October 21, 2020
Time: 2:00 – 3:00 pm Eastern
To register:

After the conclusion of the program, there will be a separate question and answer session for investors and analysts. A recording of the event will be archived on the company’s website.

The Company’s products are currently not approved for commercial distribution in the United States. Motiva Implants® are undergoing clinical investigation pursuant to U.S. FDA regulations for investigational medical devices.  

About Establishment Labs

Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at  

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “would,” “may” or other similar expressions in this press release, and includes statements related to our ongoing clinical trials and our ability to commercialize Motiva Ergonomix implants. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the Company’s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results may differ from our expectations, and those differences may be material. Factors that could cause or contribute to these differences include, among others, those risks and uncertainties discussed in the Company’s annual report on Form 10-K filed on March 16, 2020, quarterly reports on Form 10-Q, and other filings made by the Company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.


Contact Data